Ligelizumab

DB11856

biotech investigational

Deskripsi

Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE). Similar in mechanism to omalizumab, another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer a greater affinity for free serum IgE and an altered sensitivity to IgE conformation.A242292

Ligelizumab is currently under investigation for the treatment of chronic spontaneous urticaria (CSU), an autoimmune-driven inflammatory condition. While the precise pathogenesis of CSU is not entirely clear, autoantibodies against IgE receptors, and sometimes against IgE itself, are thought to exist in 30-40% of patients,A242362,A242367 and the efficacy anti-IgE antibody therapy in the treatment of CSU has been previously established with omalizumab. Initial trials of ligelizumab suggest a greater efficacy over its predecessor for the treatment of CSU.A242367

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Ligelizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Ligelizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Ligelizumab.
Estrone Estrone may increase the thrombogenic activities of Ligelizumab.
Estradiol Estradiol may increase the thrombogenic activities of Ligelizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Ligelizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Ligelizumab.
Mestranol Mestranol may increase the thrombogenic activities of Ligelizumab.
Estriol Estriol may increase the thrombogenic activities of Ligelizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Ligelizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Ligelizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Ligelizumab.
Tibolone Tibolone may increase the thrombogenic activities of Ligelizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ligelizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ligelizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Ligelizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Ligelizumab.
Zeranol Zeranol may increase the thrombogenic activities of Ligelizumab.
Equol Equol may increase the thrombogenic activities of Ligelizumab.
Promestriene Promestriene may increase the thrombogenic activities of Ligelizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Ligelizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Ligelizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Ligelizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Ligelizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Ligelizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Ligelizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Ligelizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Ligelizumab.
Formononetin Formononetin may increase the thrombogenic activities of Ligelizumab.
Estetrol Estetrol may increase the thrombogenic activities of Ligelizumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ligelizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ligelizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ligelizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ligelizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Ligelizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ligelizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ligelizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Ligelizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ligelizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ligelizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ligelizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ligelizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ligelizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ligelizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Ligelizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ligelizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ligelizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ligelizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ligelizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Ligelizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Ligelizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Ligelizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ligelizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ligelizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Ligelizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Ligelizumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ligelizumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Ligelizumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Ligelizumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Ligelizumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Ligelizumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Ligelizumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Ligelizumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Ligelizumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Ligelizumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Ligelizumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Ligelizumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Ligelizumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Ligelizumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Ligelizumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Ligelizumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Ligelizumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ligelizumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Ligelizumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Ligelizumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Ligelizumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Ligelizumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Ligelizumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Ligelizumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Ligelizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Ligelizumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Ligelizumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Ligelizumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Ligelizumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ligelizumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Ligelizumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Ligelizumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ligelizumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Ligelizumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Ligelizumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Ligelizumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Ligelizumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Ligelizumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Ligelizumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Ligelizumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Ligelizumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ligelizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Ligelizumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Ligelizumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Ligelizumab.

Target Protein

Immunoglobulin heavy constant epsilon IGHE

Referensi & Sumber

Artikel (PubMed)
  • PMID: 33459118
    Kaplon H, Reichert JM: Antibodies to watch in 2021. MAbs. 2021 Jan-Dec;13(1):1860476. doi: 10.1080/19420862.2020.1860476.
  • PMID: 31913280
    Gasser P, Tarchevskaya SS, Guntern P, Brigger D, Ruppli R, Zbaren N, Kleinboelting S, Heusser C, Jardetzky TS, Eggel A: The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020 Jan 8;11(1):165. doi: 10.1038/s41467-019-13815-w.
  • PMID: 30033911
    Saini SS, Kaplan AP: Chronic Spontaneous Urticaria: The Devil's Itch. J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1097-1106. doi: 10.1016/j.jaip.2018.04.013.
  • PMID: 31577874
    Maurer M, Gimenez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, Bernstein JA, Brehler R, Chu CY, Chung WH, Danilycheva I, Grattan C, Hebert J, Katelaris C, Makris M, Meshkova R, Savic S, Sinclair R, Sitz K, Staubach P, Wedi B, Loffler J, Barve A, Kobayashi K, Hua E, Severin T, Janocha R: Ligelizumab for Chronic Spontaneous Urticaria. N Engl J Med. 2019 Oct 3;381(14):1321-1332. doi: 10.1056/NEJMoa1900408.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul